153
Participants
Start Date
August 17, 2017
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
[11C]raclopride plus placebo
Placebo (po) will be given 60 minutes prior to \[11C\]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
[11C]raclopride plus drug
Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
[11C]NNC-112
\[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
National Institutes of Health Clinical Center, Bethesda
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH